Key result
The first-order derivative UV spectroscopy method successfully quantified rupatadine and montelukast in a combined tablet formulation with mean recoveries of 99.59% and 99.21%, respectively.
The study developed a valid first-order derivative UV spectroscopy method for the simultaneous estimation of rupatadine and montelukast in combined tablets without prior separation.
May support combined-tablet quality control; leaves open multi-lab validation and regulatory adoption.
This study describes the development and validation for the simultaneous estimation of rupatadine and montelukast by the Þ rst-order derivative UV spectroscopy method. The quantiÞ cation was achieved by the Þ rstorder derivative spectroscopy method at 273.46 nm and 297.27 nm over the concentration range of 5-25 µg/ ml for estimation of rupatadine and montelukast in a combined tablet formulation. Procedure does not require prior separation of components from the sample. Rupatadine and montelukast were determined at 15 µg/ml with a mean recovery of 99.59 + 0.225 and 99.21 + 0.76, respectively. Calibration curves were linear with a correlation coefÞ cient of 0.9994 and 0.9992 for rupatadine and montelukast, respectively. The relative standard deviation was found to be Key words: Combination tablet, Þ rst-order derivative spectroscopy, montelukast, rupatadine.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2009) studied this question. First-order derivative UV spectroscopy method was evaluated on Simultaneous estimation of rupatadine and montelukast. The first-order derivative UV spectroscopy method successfully quantified rupatadine and montelukast in a combined tablet formulation with mean recoveries of 99.59% and 99.21%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: